Molina Healthcare (MOH) shares plummeted over 26% Friday to close at $131.65 after the company reported a massive earnings miss and issued a bleak financial outlook for the coming year.
The dramatic sell-off drove the stock to a new 52-week low, erasing months of steady performance in a single trading session.
| Current Price | $130.52 |
| Daily Change | -26.19% 🔴 |
| Day Range | $125.11 – $136.26 |
| 52-Week Range | $125.11 – $359.97 |
| Volume | 2.15M |
The decline was triggered by the company’s fourth-quarter 2025 results, which revealed an adjusted loss that caught Wall Street off guard.
According to financial reports, the quarterly results were overshadowed by surging medical costs and deteriorating margins that have led management to significantly lower expectations for 2026.
This making it a critical case study in how to analyze a stock based on fundamental profitability.
Despite the sharp drop, the company did report a slight beat on the top line, though this was not enough to offset investor concerns regarding rising utilization rates.
Prior to this event, the stock had shown positive momentum, trading up about 2% for the year.
Key Takeaways
- MOH stock plummeted over 26% to $130.52, hitting a new 52-week low.
- The company reported a Q4 adjusted loss of $2.75 per share, missing consensus by $3.18.
- Management slashed 2026 guidance to a minimum of $5.00 per share, a 55% decline from 2025 levels.
- Medical Care Ratio (MCR) climbed to 91.7% for the full year 2025.
- Molina announced plans to exit its Medicare Advantage Part D product by 2027.
Why Did Molina Healthcare (MOH) Stock Plummet 26% Today?
The primary driver behind today's collapse was a combination of a massive quarterly earnings miss and a drastic reduction in future profit forecasts.
Shares traded as low as $125.00 during the session on a heavy volume of more than 2.1 million shares.
The move marks a stark reversal for a stock that opened the day at a prior close of $176.84. The sudden decline pushed the company well below its previous 52-week high of $359.97.
Market data shows the stock has now fallen nearly 27% over the last month and roughly 59% over the past year.
This underperformance reflects growing market anxiety over the company’s ability to manage medical costs in its core Medicaid segment, which many investors track closely using the best stock analysis apps to monitor real-time volatility.
Q4 Earnings Miss and Drastically Reduced 2026 Guidance Fuel Sell-Off
Molina’s fourth-quarter 2025 results were significantly worse than analysts anticipated. The company reported an adjusted loss of $2.75 per share, while analysts had expected a profit of $0.43.
This resulted in a staggering earnings miss of $3.18 per share. While quarterly revenue reached $11.38 billion, exceeding estimates by over 5%, the higher revenue could not compensate for the deepening losses.
The outlook for 2026 further fueled the panic. Management introduced 2026 adjusted earnings guidance of at least $5.00 per share.
This represents a nearly 55% collapse from the $11.03 reported for the full year 2025, a shift that perfectly illustrates how market forces and earnings expectations dictate immediate price action.
Additionally, the company expects 2026 premium revenue to decline by 2% to approximately $42.2 billion.
| Event Impact Analysis | Value |
|---|---|
| Q4 EPS (Actual) | -$2.75 |
| Q4 EPS (Consensus) | $0.43 |
| 2025 EPS (Full Year) | $11.03 |
| 2026 EPS Guidance (Min) | $5.00 |
| Earnings Miss Magnitude | -$3.18 |
Rising Medical Costs and Operational Headwinds Weigh Heavily
A primary cause of the earnings deterioration is the Consolidated Medical Care Ratio (MCR), which reached 91.7% for 2025.
This metric reflects the percentage of premiums spent on medical claims; a higher ratio indicates lower profitability.
Molina faced approximately $2.00 per share in unfavorable retroactive revenue items during the quarter, further straining the bottom line.
The company is also grappling with specific operational burdens. A new Medicaid contract is expected to create a $2.50 per share headwind for the 2026 guidance.
Furthermore, membership fell nearly 1% year over year to 5.49 billion, missing the consensus estimate of 5.52 billion.
To mitigate long-term losses, Molina plans to exit its underperforming Medicare Advantage Part D product by 2027.
What Are Analysts Saying About Molina Healthcare's Outlook?
Following the report, several analyst firms adjusted their expectations. According to Barron's, the disappointing outlook was the primary catalyst for the sharp drop.
TD Cowen downgraded the stock from “buy” to “hold” and set a price target of $203.
- UBS Group: Reduced price target from $180 to $170 with a neutral rating.
- Deutsche Bank: Issued a price target of $165.
- Jefferies Financial Group: Set a price target of $160.
- Sanford C. Bernstein: Maintained an outperform rating but with a price target of $224.
| Analyst Firm | Price Target | Rating Change |
|---|---|---|
| TD Cowen | $203.00 | Buy to Hold 🔴 |
| UBS Group | $170.00 | Reduced PT 🔴 |
| Deutsche Bank | $165.00 | – |
| Jefferies Financial Group | $160.00 | – |
| Sanford C. Bernstein | $224.00 | Maintained |
How Does MOH Compare to Its Healthcare Peers?
Molina Healthcare significantly underperformed its sector on Friday.
While MOH fell more than 26%, the healthcare plans industry average actually rose about 1.3%.
Most of Molina’s peers saw gains, reflecting that the company’s struggles are largely business-specific rather than a sector-wide trend.
For comparison, The Cigna Group (CI) rose about 3%, and CVS Health Corporation (CVS) gained over 3%.
Centene Corporation (CNC) was one of the few other peers to see a decline, falling nearly 6%, but its losses were far less severe than Molina’s.
This divergence suggests that investors are specifically concerned about Molina’s concentration in the Medicaid managed care sector, even though healthcare stocks are typically classified as non-cyclical stocks that provide defensive positioning during market volatility.
| Company | Symbol | Daily Change | Market Cap |
|---|---|---|---|
| The Cigna Group | CI | +3.06% 🟢 | N/A |
| CVS Health Corp | CVS | +3.31% 🟢 | N/A |
| Centene Corp | CNC | -5.74% 🔴 | N/A |
| Humana Inc. | HUM | +0.60% 🟢 | N/A |
| Molina Healthcare | MOH | -26.19% 🔴 | N/A* |
| Industry Avg | – | +1.32% 🟢 | – |
What Should Investors Watch Next for Molina Healthcare?
Investors will likely focus on whether the company can successfully navigate what CEO Joseph Zubretsky described as a “trough year” for Medicaid margins in 2026.
Zubretsky expressed optimism regarding a future earnings trajectory, citing anticipated rate restorations.
However, the burden of new contracts and the planned exit from Medicare Advantage Part D will remain significant factors through 2027.
Institutional activity prior to the drop showed some confidence, with Merit Financial Group LLC raising its stake by almost 290% in the third quarter.
However, internal moves may draw scrutiny; Director Richard M. Schapiro sold $357 shares at $143.02 in late 2025.
Investors will be watching for any further adjustments to the 2026 guidance, as such negative forecasts are often a primary signal for when to sell a stock that has shifted its growth narrative.
The Bottom Line
Molina Healthcare is facing a period of intense operational pressure as medical costs rise and Medicaid membership fluctuates.
While the revenue beat offers a small silver lining, the massive guidance cut suggests that the company’s profitability will remain under significant strain through at least 2026.
Investors will need to weigh management's long-term optimism against the immediate reality of deteriorating margins and a “trough” in earnings performance.
